DMS/NIGMS 1: Developing a mathematical framework to understand viral-cellular transduction for cellular reprogramming

NSF Award Search · 01002526DB NSF RESEARCH & RELATED ACTIVIT · $500,000 · view on nsf.gov ↗

Abstract

Genetically engineered cell therapies are transforming how doctors treat challenging diseases like cancer, sickle cell disease, HIV, and autoimmune conditions. These treatments work by giving a patient’s own cells a new ability to find and fight disease more effectively. A crucial step in making these cell therapies accessible is by swiftly delivering new genetic material into cells using viral vectors in a liquid medium. Porous materials that guide the flow of cells and viruses dramatically improve delivery, but we do not yet fully understand how they work. Understanding how porous materials enhance cell therapy production will help make cell therapies more reliable and affordable for patients in dire need of treatment. This project will use artificial intelligence, computer modeling and experiments to determine how flow inside porous materials efficiently produces genetically modified cells. In answering this important scientific question, this project will engage students from the high school to graduate levels and help train future scientists and engineers. By integrating research outcomes in classrooms and through partnerships with industries and foundations, this work will also help spread awareness of advanced engineered cell therapies and how they can improve health outcomes. This research will develop a mechanistic understanding of how liquid flow in microfluidic devices and porous scaffolds enhances the efficiency of viral transduction in engineered cell therapie

Key facts

NSF award ID
2451660
Awardee
North Carolina State University (NC)
SAM.gov UEI
U3NVH931QJJ3
PI
Andrey V Kuznetsov
Primary program
01002526DB NSF RESEARCH & RELATED ACTIVIT
All programs
Artificial Intelligence (AI), Machine Learning Theory, NSF/NIGMS Initiative-Mathematical Bio, Biotechnology
Estimated total
$500,000
Funds obligated
$500,000
Transaction type
Standard Grant
Period
09/01/2025 → 08/31/2028